18 May 2021
AEGIS-H2H study results published in Inflammatory Bowel Diseases
Shield Therapeutics plc, notes the recent publication in the journal Inflammatory Bowel Diseases of positive long-term results from a study comparing the effectiveness of ferric maltol 30 mg bid with intravenous (IV) iron (ferric carboxymaltose given according to each centre’s standard practice) over 52 weeks. The primary endpoint was haemoglobin responder rate (≥2 g/dL increase or normalization) at week 12, with a 20% noninferiority limit in the intent-to-treat and per protocol populations.
For further details click here.